ArticleEye (London, England)2026
Selective laser trabeculoplasty (SLT) outcomes following topical therapy.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis real-world, retrospective review of SLT outcomes at Lancashire Teaching Hospitals NHS Foundation Trust aimed to establish whether there is any net benefit in using topical drop treatment prior to SLT compared with proceeding directly to SLT as a first-line treatment. Several studies have shown that SLT gives the greatest reduction in intraocular pressure (IOP) for eyes that have not received prior treatment with drops. Here, we look at different topical therapies used prior to SLT and investigate SLT efficacy following these.
methodData were collected from 196 SLT naïve eyes with ocular hypertension or primary open-angle glaucoma who underwent SLT between January 2022 and May 2022. The eyes had received either no prior topical therapy or one or more topical IOP-lowering agents.
resultsNo significant difference was found in the overall reduction in IOP after SLT between eyes treated with prostaglandin analogue (PGA) drops alone prior to SLT (7.89 mmHg, n = 74) and eyes that received SLT as first-line treatment (6.88 mmHg, n = 56). Eyes also treated with beta-blockers did show a greater reduction in IOP.
conclusionThis retrospective study, based in a UK NHS centre, found no significant benefit in using PGA drops prior to SLT compared to SLT as first-line treatment for lowering IOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.